Definium Therapeutics Issues Inducement Stock Options to New Hires

Definium Therapeutics ( (DFTX) ) has provided an announcement.

Definium Therapeutics has granted stock options to two newly hired non-executive employees as inducement awards, covering an aggregate of 28,640 common shares with an exercise price set at the closing market price on the February 2, 2026 grant date. The options, approved by the company’s compensation committee under Nasdaq inducement grant rules and issued outside existing equity plans, will vest over four years, underscoring Definium’s use of equity-based incentives to attract and retain talent as it advances its late-stage pipeline in psychiatric and neurological care.

The most recent analyst rating on (DFTX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Definium Therapeutics stock, see the DFTX Stock Forecast page.

Spark’s Take on DFTX Stock

According to Spark, TipRanks’ AI Analyst, DFTX is a Neutral.

The score is held back mainly by weak financial performance (no revenue, sizeable ongoing losses, and heavy cash burn), partially offset by a stronger near-term setup from the earnings call (financing runway and clear Phase III catalysts) and supportive technical momentum. Valuation remains challenging due to negative earnings and no dividend support.

To see Spark’s full report on DFTX stock, click here.

More about Definium Therapeutics

Definium Therapeutics, formerly Mind Medicine (MindMed) Inc., is a late-stage clinical biopharmaceutical company focused on developing a new generation of therapeutics to address the underlying causes of psychiatric and neurological disorders. Headquartered in New York and listed on Nasdaq under the symbol DFTX, the company applies scientific rigor to psychedelics with the goal of delivering accessible mental health treatments at scale.

Average Trading Volume: 1,865,228

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.72B

Learn more about DFTX stock on TipRanks’ Stock Analysis page.